Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status

Advances in Therapy

Volumn 26, Issue 10, 2009, Pages 893-907

  Stein, Lance L ^a   Dong, Mamie H ^b   Loomba, Rohit ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Exenatide; Hepatic steatosis; Insulin resistance; Insulin sensitizers; Metformin; Nonalcoholic fatty liver disease; Pioglitazone; Rimonabant; Rosiglitazone; Troglitazone

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ACETYLCYSTEINE; ALPHA TOCOPHEROL; BIGUANIDE DERIVATIVE; CANNABINOID 1 RECEPTOR ANTAGONIST; EXENDIN 4; GLITAZONE DERIVATIVE; INCRETIN; INSULIN SENSITIZING AGENT; METFORMIN; OTENABANT; PIOGLITAZONE; PLACEBO; RIMONABANT; ROSIGLITAZONE; TARANABANT; TROGLITAZONE; URSODEOXYCHOLIC ACID;

CALORIC INTAKE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DIABETES MELLITUS; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FLUID RETENTION; FRACTURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MENTAL DISEASE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PREVALENCE; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

FATTY LIVER; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; PREVALENCE; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 73949147212     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0072-z     Document Type: Review

References (57)

1. A. Fraser M.P. Longnecker D.A. Lawlor 2007 Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004 Gastroenterology 133 1814 1820 10.1053/j.gastro.2007.08.077 1:CAS:528: DC%2BD1cXnt1Kqsw%3D%3D 18054554 (Pubitemid 350186161)
2. S.R. Bloom F.P. Kuhajda I. Laher 2008 The obesity epidemic: pharmacological challenges Mol Interv. 8 82 98 10.1124/mi.8.2.6 1:CAS:528:DC%2BD1cXmtFOku7o%3D 18403653 (Pubitemid 351565658)
3. A. Wieckowska A.E. Feldstein 2008 Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive Semin Liver Dis. 28 386 395 10.1055/s-0028-1091983 1:CAS:528:DC%2BD1cXhsVKisr7N 18956295
4. E.E. Powell W.G. Cooksley R. Hanson J. Searle J.W. Halliday L.W. Powell 1990 The natural history of nonalcoholic steatohepatitis: a follow-uup study of forty-two patients for up to 21 years Hepatology 11 74 80 10.1002/hep.1840110114 2295475
5. C.T. Frantzides M.A. Carlson R.E. Moore 2004 Effect of body mass index on nonalcoholic fatty liver disease in patients undergoing minimally invasive bariatric surgery J Gastrointest Surg. 8 849 855 10.1016/j.gassur.2004.07.001 15531238 (Pubitemid 41115738)
6. C.K. Argo P.G. Northup A.M. Al-OOsaimi S.H. Caldwell 2009 Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis J Hepatol. 51 371 379 10.1016/j.jhep.2009.03.019 1:CAS:528:DC%2BD1MXnvVams7g%3D 19501928
7. P. Angulo J.C. Keach K.P. Batts K.D. Lindor 1999 Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis Hepatology 30 1356 11362 10.1002/hep.510300604 1:STN:280:DC%2BD3c%2Fkt1ejtQ%3D%3D 10573511
8. J.M. Clark F.L. Brancati A.M. Diehl 2003 The prevalence and etiology of elevated aminotransferase levels in the United States Am J Gastroenterol. 98 960 967 10.1111/j.1572-0241.2003.07486.x 1:CAS:528:DC%2BD3sXksVentro%3D 12809815 (Pubitemid 36733754)
9. C.P. Day O.F. James 1998 Steatohepatitis: a tale of two "hits"? Gastroenterology 114 842 845 10.1016/S0016-5085(98)70599-2 1:STN:280: DyaK1c3htFartQ%3D%3D 9547102 (Pubitemid 28160420)
10. A.J. Sanyal C. Campbell-SSargent F. N. s. a. o. i. r. abnormalities. Mirshahi 2001 Gastroenterology 120 1183 11192 10.1053/gast.2001.23256 1:CAS:528:DC%2BD3MXjtVeqsb8%3D 11266382
11. R. Loomba S.J. Hwang C.J. O'Donnell 2008 Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham Heart Study Gastroenterology 134 953 959 10.1053/j.gastro.2008.01.037 1:CAS:528: DC%2BD1cXls1Gmurs%3D 18395076
12. M. Hamaguchi T. Kojima N. Takeda 2005 The metabolic syndrome as a predictor of nonalcoholic fatty liver disease Ann Intern Med. 143 722 728 1:CAS:528:DC%2BD2MXht1yntLrN 16287793
13. H. Kang J.K. Greenson J.T. Omo 2006 Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD Am J Gastroenterol. 101 2247 2253 10.1111/j.1572-0241.2006. 00719.x 1:CAS:528:DC%2BD28Xht1SqsbnP 17032189 (Pubitemid 44477551)
14. G. Marchesini E. Bugianesi G. Forlani 2003 Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome Hepatology 37 917 923 10.1053/jhep.2003.50161 12668987 (Pubitemid 36397405)
15. S. Bellentani R. Dalle Grave A. Suppini G. Marchesini 2008 Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach Hepatology 47 746 754 10.1002/hep.22009 18098321 (Pubitemid 351280743)
16. R. Vuppalanchi N. Chalasani 2009 Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management Hepatology 49 306 317 10.1002/hep.22603 19065650
17. M.A. Huang J.K. Greenson C. Chao 2005 One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study Am J Gastroenterol. 100 1072 1081 10.1111/j.1572-0241.2005.41334.x 15842581 (Pubitemid 40769044)
18. Y.L. Woods J.R. Petrie C. Sutherland 2009 Dissecting insulin signaling pathways: individualised therapeutic targets for diagnosis and treatment of insulin resistant states Endocr Metab Immune Disord Drug Targets 9 187 198 10.2174/187153009788452408 1:CAS:528:DC%2BD1MXmvFCgt78%3D 19519467
19. G. Zhou R. Myers Y. Li 2001 Role of AMP-activated protein kinase in mechanism of metformin action J Clin Invest. 108 1167 1174 1:CAS:528: DC%2BD3MXns1ChsL4%3D 11602624
20. H.Z. Lin S.Q. Yang C. Chuckaree F. Kuhajda G. Ronnet A.M. Diehl 2000 Metformin reverses fatty liver disease in obese, leptin-deficient mice Nat Med. 6 998 1003 10.1038/79697 1:CAS:528:DC%2BD3cXmslSjsro%3D 10973319
21. G. Marchesini M. Brizi G. Bianchi S. Tomassetti M. Zoli N. Melchionda 2001 Metformin in non-alcoholic steatohepatitis Lancet 358 893 894 10.1016/S0140-6736(01)06042-1 1:CAS:528:DC%2BD3MXmvVKmtr4%3D 11567710 (Pubitemid 32900577)
22. S. Nair A.M. Diehl M. Wiseman G.H. Farr Jr. R.P. Perrillo 2004 Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial Aliment Pharmacol Ther. 20 23 28 10.1111/j.1365-2036.2004.02025.x 1:CAS:528:DC%2BD2cXmsl2lt7Y%3D 15225167 (Pubitemid 38938715)
23. A. Uygun A. Kadayifci A.T. Isik 2004 Metformin in the treatment of patients with non-alcoholic steatohepatitis Aliment Pharmacol Ther. 19 537 544 10.1111/j.1365-2036.2004.01888.x 1:CAS:528:DC%2BD2cXjt1Gqsbg%3D 14987322 (Pubitemid 38387180)
24. E. Bugianesi E. Gentilcore R. Manini 2005 A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease Am J Gastroenterol. 100 1082 1090 10.1111/j.1572-0241.2005.41583.x 1:CAS:528:DC%2BD2MXkvVSms7Y%3D 15842582 (Pubitemid 40769045)
25. A. Duseja A. Das R.K. Dhiman 2007 Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions Ann Hepatol. 6 222 226 1:CAS:528:DC%2BD1cXhtFemsrfJ 18007551
26. F. Akyuz K. Demir S. Ozdil 2007 The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease Dig Dis Sci. 52 2359 2367 10.1007/s10620-006-9145-x 1:CAS:528:DC%2BD2sXoslGisrc%3D 17429734 (Pubitemid 47246475)
27. C.P. de Oliveira J.T. Stefano E.R. de Siqueira 2008 Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis Hepatol Res. 38 159 165 18197877
28. R. Idilman D. Mizrak D. Corapcioglu 2008 Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis Aliment Pharmacol Ther. 28 200 208 10.1111/j.1365-2036.2008.03723.x 1:CAS:528:DC%2BD1cXps1Gmt74%3D 18445142 (Pubitemid 351861962)
29. Loomba R, Lutchman G, Kleiner DE, et al. Clinical trial: pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2008. In press.
30. A. Nar O. Gedik 2009 The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease Acta Diabetol. 46 113 118 10.1007/s00592-008-0067-2 1:CAS:528:DC%2BD1MXlsFKksr8%3D 18839053
31. Omer Z, Cetinkalp S, Akyildiz M, et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2009. In press.
32. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or nonalcoholic steatohepatitis. Cochrane Database Syst Rev. 2007;(1):CD005166.
33. M. Bajaj S. Suraamornkul P. Piper 2004 Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients J Clin Endocrinol Metab. 89 200 206 10.1210/jc.2003-031315 1:CAS:528:DC%2BD2cXmvFequg%3D%3D 14715850 (Pubitemid 38183882)
34. G. Lutchman K. Promrat D.E. Kleiner 2006 Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement Clin Gastroenterol Hepatol. 4 1048 1052 10.1016/j.cgh.2006.05.005 1:CAS:528:DC%2BD28XptFWmt7w%3D 16814613 (Pubitemid 44118842)
35. L.G. Fryer A. Parbu-Patel D. Carling 2002 The antidiabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways J Biol Chem. 277 25226 25232 10.1074/jbc.M202489200 1:CAS:528:DC%2BD38XlsVWiurc%3D 11994296 (Pubitemid 34951829)
36. D.K. Coletta A. Sriwijitkamol E. Wajcberg, et al. 2009 Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial Diabetologia 52 723 732 10.1007/s00125-008-1256-9 1:CAS:528:DC%2BD1MXisFSisr8%3D 19169664
37. C.R. Dormuth G. Carney B. Carleton K. Bassett J.M. Wright 2009 Thiazolidinediones and fractures in men and women Arch Intern Med. 169 1395 1402 10.1001/archinternmed.2009.214 1:CAS:528:DC%2BD1MXhtVOmtr3N 19667303
38. S.E. Nissen K. Wolski 2007 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med. 356 2457 2471 10.1056/NEJMoa072761 1:CAS:528:DC%2BD2sXms1SisrY%3D 17517853 (Pubitemid 46919772)
39. S.H. Caldwell E.E. Hespenheide J.A. Redick J.C. Iezzoni E.H. Battle B.L. Sheppard 2001 A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis Am J Gastroenterol. 96 519 525 10.1111/j.1572-0241. 2001.03553.x 1:CAS:528:DC%2BD3MXisVGhtLc%3D 11232700
40. B.A. Neuschwander-Tetri E.M. Brunt K.R. Wehmeier D. Oliver B.R. Bacon 2003 Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone Hepatology 38 1008 1017 1:CAS:528: DC%2BD3sXovFGhurc%3D 14512888
41. K. Promrat G. Lutchman G.I. Uwaifo 2004 A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis Hepatology 39 188 196 10.1002/hep.20012 1:CAS:528:DC%2BD2cXjtlCrurc%3D 14752837 (Pubitemid 38461481)
42. A.J. Sanyal P.S. Mofrad M.J. Contos 2004 A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis Clin Gastroenterol Hepatol. 2 1107 1115 10.1016/S1542-3565(04) 00457-4 1:CAS:528:DC%2BD2MXntFyisA%3D%3D 15625656 (Pubitemid 40037642)
43. R. Belfort S.A. Harrison K. Brown, et al. 2006 A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med. 355 2297 2307 10.1056/NEJMoa060326 1:CAS:528:DC%2BD28Xht1OrtrvI 17135584 (Pubitemid 44837778)
44. C.H. Wang C.H. Leung S.C. Liu C.H. Chung 2006 Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic fatty liver disease J Formos Med Assoc. 105 743 752 10.1016/S0929-6646(09)60202-3 1:CAS:528:DC%2BD28XhtFOrtrjO 16959622
45. G.P. Aithal J.A. Thomas P.V. Kaye 2008 Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis Gastroenterology 135 1176 1184 10.1053/j.gastro.2008.06.047 1:CAS:528: DC%2BD1cXht12lurrN 18718471
46. V. Ratziu P. Giral S. Jacqueminet 2008 Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial Gastroenterology 135 100 110 10.1053/j.gastro.2008.03.078 1:CAS:528:DC%2BD1cXps1Wltrc%3D 18503774 (Pubitemid 351916703)
47. N.P. Chalasani A.J. Sanyal K.V. Kowdley 2009 Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design Contemp Clin Trials 30 88 96 10.1016/j.cct.2008.09.003 1:CAS:528:DC%2BD1cXhsFagsrbE 18804555
48. X. Ding N.K. Saxena S. Lin N.A. Gupta F.A. Anania 2006 Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice Hepatology 43 173 181 10.1002/hep.21006 1:CAS:528: DC%2BD28Xpt1Snsw%3D%3D 16374859 (Pubitemid 43733604)
49. D.C. Klonoff J.B. Buse L.L. Nielsen 2008 Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin. 24 275 286 1:CAS:528:DC%2BD1cXhvVOgtLs%3D 18053320
50. M.E. Tushuizen M.C. Bunck P.J. Pouwels J.H. van Waesberghe M. Diamant R.J. Heine 2006 Incretin mimetics as a novel therapeutic option for hepatic steatosis Liver Int. 26 1015 1017 10.1111/j.1478-3231.2006.01315.x 16953843 (Pubitemid 44323421)
51. T. Nagasawa Y. Inada S. Nakano 2006 Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and cholinedeficient diet Eur J Pharmacol. 536 182 191 10.1016/j.ejphar.2006.02.028 1:CAS:528:DC%2BD28Xjs1ajs7s%3D 16574099
52. M. Pang S.M. de la Monte L. Longato 2009 PPAR-delta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair J Hepatol. 50 1192 1201 10.1016/j.jhep.2009.01.021 1:CAS:528: DC%2BD1MXlslWms78%3D 19398227
53. S.M. Reilly C.H. Lee 2008 PPAR delta as a therapeutic target in metabolic disease FEBS Lett. 582 26 31 10.1016/j.febslet.2007.11.040 1:CAS:528: DC%2BD2sXhsVOltb3O 18036566 (Pubitemid 350297247)
54. R. Nogueiras F. Rohner-Jeanrenaud S.C. Woods M.H. Tschop 2008 The endocannabinoid system and the control of glucose homeostasis J Neuroendocrinol. 20 suppl.1 147 151 10.1111/j.1365-2826.2008.01692.x 1:CAS:528: DC%2BD1cXlsl2iu7g%3D 18426514 (Pubitemid 351552686)
55. L.F. Van Gaal A.M. Rissanen A.J. Scheen O. Ziegler S. Rossner 2005 Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 365 1389 1397 10.1016/S0140-6736(05)66374-X 15836887 (Pubitemid 40523733)
56. F.X. Pi-Sunyer L.J. Aronne H.M. Heshmati J. Devin J. Rosenstock 2006 Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial JAMA 295 761 775 10.1001/jama.295.7.761 1:CAS:528:DC%2BD28XhsFOrs7g%3D 16478899 (Pubitemid 43244304)
57. D.R. Janero A. Makriyannis 2009 Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis Expert Opin Emerg Drugs 14 43 65 10.1517/14728210902736568 1:CAS:528: DC%2BD1MXivFSmtbc%3D 19249987